VIA
CTMX icon

Virtus Investment Advisers’s CytomX Therapeutics CTMX Stock Holding History

Virtus Investment Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408K Buy
108,703
+43,623
+67% +$167K 0.1% 268
2026
Q1 		$306K Buy
65,080
+1,589
+3% +$8.07K 0.08% 274
2025
Q4 		$270K Buy
+63,491
New +$241K 0.07% 289

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Virtus Investment Advisers's CTMX Position: Q2 2026 in Review

Virtus Investment Advisers increased its CytomX Therapeutics (CTMX) stake by 67% in Q2 2026, buying an estimated $167K and bringing the position to 108,703 shares worth $408K. The position accounts for 0.1% of the portfolio, ranked #268.

Virtus Investment Advisers first reported a position in CTMX in Q4 2025 and has held it in 3 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Virtus Investment Advisers held 108,703 shares of CytomX Therapeutics worth $408K as of Q2 2026.
  • Virtus Investment Advisers bought 43,623 CytomX Therapeutics shares in Q2 2026, an estimated $167K.
  • CytomX Therapeutics made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #268 holding.
  • Virtus Investment Advisers first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.